Dendreon's John Osborn has joined Onyx Pharmaceuticals as senior VP, global corporate affairs.
In his new role at the US-based biopharma, he will lead the company's public and government affairs activities, as well as key stakeholder relationships.
Osborn's most recent position was executive VP, general counsel and secretary at Dendreon, which markets cancer vaccine Provenge.
Prior to his time at Dendreon, he held similar roles at US Oncology and Cephalon.
He also spent time serving with the US Department of State and was a member of the bipartisan United States Advisory Commission on Public Diplomacy in 2008.
“As a lawyer, policy advocate and former diplomat, John brings a diverse and extensive background to Onyx, with broad experience across the life sciences industry and the US government,” said Dr Anthony Coles, president and CEO of Onyx.
“John is a proven leader and his unique expertise aligns well with our plan for global growth as a multi-product company reaching patients around the world.”